This week, Bobbi Conner talks with MUSC's Dr. Christina Mingora about the impact of recent advances in treating cystic ...

Avalyn has initiated the AURA Phase II clinical trial assessing the efficacy and safety of AP02, inhaled nintedanib delivered ...

Avalyn, a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the initiation of the AURA ...

Vanzacaftor-tezacaftor-deutivacaftor, a novel therapeutic, once-daily drug, demonstrates noninferiority to elexacaftor-tezacaftor-ivacaftor (the twice-daily, standard-of-care drug) in lung function ...

A review and meta-analysis of 19 studies involving 51 cystic fibrosis patients finds bacteriophage therapy was safe and ...

Researchers are developing a new therapeutic approach that uses nanoparticles for the treatment of skin and lung fibrosis, conditions that can result in severe damage to the body's tissues.

Please provide your email address to receive an email when new articles are posted on . Few patients with cystic fibrosis have a copy of the 3849+10kb C-to-T splicing mutation. Research is planned to ...

RIT biomedical engineering researchers identify a protein that can reduce fibrosis and slow disease progression.

Announcing a new article publication for BIO Integration journal. Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and ...

New molecular insights into the link between hepatocellular carcinoma and intratumoral fibrosis could lead to better ...